DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Laurence-Moon syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLaurence-Moon syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for laurence-moon syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The Laurence-Moon-Biedl syndrome is a rare, ill-defined symptom complex. The cardinal features listed across the 1956 and 1966 reports are obesity, retinitis pigmentosa, polydactyly, mental retardation, hypogonadism, and familial incidence. Only 20 to 30 per cent of the roughly 300 cases described by 1956 exhibited all six features. A 1966 review notes that the syndrome had been presented to a psychiatric hospital as a behaviour disorder, and that one patient had been misdiagnosed with Cushing’s syndrome. The same review questions the validity of viewing the symptom aggregate as a discrete, genetically transmitted syndrome, and suggests that the mental deficiency in that patient may have been secondary to brain damage rather than part of a linked complex.
A 1958 report describes four cases of the syndrome in a group of seven siblings, with one case complicated by hepato-splenomegaly. The authors note that the clinical picture varies from case to case and that the limits of the syndrome are indefinite. By 1957 about 320 cases had been described in the world literature. A 2012 paper states that the average age of diagnosis is 9 years, and that by that stage it is difficult to stop the deteriorating effects that have already started. The paper also notes overlapping phenotypes with Bardet-Biedl syndrome, making diagnosis difficult.
The 2012 paper describes a single 14-year-old patient hospitalised with poor appetite, acidity, anaemia, abdominal pain, muscle weakness, and blindness of four years’ duration. Examination revealed renal failure, polydactyly, mild obesity, and retinitis pigmentosa. The patient was given epoetin alfa (Eprex) 2000 units twice weekly, which the authors state is lower than the required and stated doses, and the route of administration (subcutaneous) was wrongly chosen compared to intravenous. Other medications were omeprazole for gastric problems and lophos for hypocalcaemia, given in normal doses. The authors conclude that substandard pharmaceutical care resulted in incomplete treatment and no monitoring of electrolytes or other fluids, leading to treatment failure.
No drug has been shown to alter the course of the syndrome itself. The 2012 paper calls for comprehensive research, noting that the recessive genetic defect needs to be exploited for better pharmaceutical care. What is still missing are prospective trials, standardised diagnostic criteria, and any evidence that pharmaceutical intervention can modify the underlying disease rather than manage individual symptoms.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Clinical Endocrinology & Metabolism · 1956 · 13 citations
LAURENCE-MOON-BIEDL SYNDROME IN AN ARAB BOY: FAMILIAL INCIDENCE
AbstractDuring the past eighty-nine years, following the report of 4 cases by Laurence and Moon (1) from the Royal Eye Hospital in London, some 300 cases of the Laurence-Moon-Biedl syndrome have been described in the medical literature (2). Of these, however, only 20 to 30 per cent have exhibited the complete picture of the syndrome comprising the six cardinal features of obesity, retinitis pigmentosa, polydactylism, mental retardation, hypogonadism and familial incidence (3). The reported patients have been of many different races—Negroes, Indians, Greeks, Jews, Bantus, Caucasians and Anglo-Saxons. The present case seems worth recording, not only because it has all the major features of the syndrome but also because, to the author’s knowledge, it is the first report of this condition in an Arab.
American Journal of Psychiatry · 1966 · 3 citations
THE LAURENCE-MOON-BIEDL SYNDROME
AbstractThe Laurence-Moon-Biedi syndrome is an ill-defined symptom complex usually presenting the signs of obesity, hypogenitalism, retinitis pigmentosa, polydactyly and mental deficiency. The case reported here is the first presented to a psychiatric hospital as a behavior disorder. In addition, this same patient, on the basis of behavior, physical appearance and laboratory determinations had been previously misdiagnosed as having Cushing's syndrome. The literature pertaining to the Laurence-Moon-Biedl syndrome is reviewed with particular reference to psychiatric and endocrinologic data. Closer psychologic scrutiny of this patient revealed that his mental deficiency may have been secondary to brain damage and not part of a genetically linked symptom complex. An appraisal of previous reports indicates a lack of effort at making this distinction in the past. The question of the usefulness and validity of viewing the symptom aggregate of Laurence-Moon-Biedl patients as a discrete, genetically transmitted syndrome is discussed.
Hepato-Splenomegaly Complicating One Out of 4 Cases of Laurence-Moon-Biedl Syndrome in a Group of Seven Siblings
AbstractThe Laurence-Moon-Biedl syndrome shows much variation in its clinical picture from case to case and the limits of this syndrome are indefinite. This clinical entity was first identified by J. Z. Laurence and R. C. Moon in 1866 and was more completely described by A. Biedl in 1922. In 1935, Cockayne, Krestin and Sorsby stated that some 30 isolated cases and 15 affected families were reported during the ten years from 1925 to 1935, and in 1939 Sorsby, Avery and Cockayne made a later review. In October, 1955, J. Todd described a case of Laurence-Moon-Biedl syndrome with paranoid psychosis in the American Journal of Mental Deficiency , and in 1950 R. A. Burn reviewed 82 cases giving the total number of reported cases as 260. Up to 1957 about 320 cases have been described in the world literature but even this number is likely to rise with the increased interest shown in this syndrome.
Canadian Journal of Applied Sciences · 2012 · 0 citations · open access
AbstractThe Laurence moon Bardet Biedl syndrome is a very rare genetic disorder in which the recessive trait of gene is defected and yet need to be exploited for the purpose to provide better pharmaceutical care to such patients. It is characterized by the obesity, retinitis pigmentosa, polydactyly, mental retardation, hypogonadism and renal failure alongwith characters of retinitis pigmentosa, spastic paraplegia, hypogonadism and mental retardation. [25] Pharmaceutical care is the direct, responsible provision of medication-related care for the purpose of achieving definite outcomes that improve a patient's quality of life.[28] There is an enhanced need to have a comprehensive research to be done on the disease and its outcomes as there are chances of overlapping phenotypes of rarer disease as Laurence moon along with Bardet Biedl, that make the diagnosis difficult. The average age of the diagnosis is 9 years and at that stage it is difficult to stop the deteriorating effects that have already started. The first known case was reported by Laurence and Moon in 1866 at the Ophthalmic Hospital in South London. Laurence—Moon—Biedl—Bardet syndrome [26] 14 years old patient was being hospitalized complaining poor appetite, acidity, anemia and abdominal pain and muscle weakness and blindness since last 4 years. Upon examination was revealed to be a patient of Laurence Moon Bardet Beidle syndrome with renal failure, polydactyl and mild obesity and retinitis pigmentosa. The patient has been given Eprex (epoetin alfa) 2000 units twice weekly i.e. lower than the required and stated doses given in the official books. Moreover the route of administration selected was wrongly choosen as sub cutaneous as compared to intravenous route. Other medications include the omeprazole for gastric problems and lophos for treatment of hypocalcemia, which were in normal doses. But the substandard pharmaceutical care is resulting in sub standard therapy and in complete treatment regimen along with no monitoring of either electrolytes or other fluids resulting in treatment failure.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
